Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: liver

Brodalumab Approved for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  March 9, 2017

Brodalumab has received FDA approval for treating plaque psoriasis in adults, with a Boxed Warning against prescribing it for patients with a history of suicidal thoughts or behavior…

Filed under:Biologics/DMARDsDrug Updates Tagged with:brodalumabFDAFood and Drug Administrationplaque psoriasis

ACR Puts Forward Principles on Patient Access to Care

Mary Beth Nierengarten  |  March 1, 2017

As the 115th Congress and the Trump administration consider potential reforms to the healthcare system, including actions related to the Affordable Care Act (ACA), physicians around the country remain vitally concerned about the need to preserve and improve access to care for their patients. To that end, the ACR continues to lobby for policies that…

Filed under:Legislation & AdvocacyPractice SupportProfessional Topics Tagged with:Access to carechronic arthritishealthcare coveragehealthcare provisionsongoing careposition statementrheumatic diseases

ACR Releases New Position Statements on Site of Service & Compounding

Mary Beth Nierengarten  |  March 1, 2017

Patient Safety & Site of Service for Biologics Although emphasizing its strong support for the use of biologic agents as necessary treatments for rheumatic diseases, the ACR Board of Directors continues to be concerned about the safe delivery of these agents, given the potential for associated adverse events and infusion reactions. In a position statement…

Filed under:Biologics/DMARDsLegislation & Advocacy Tagged with:biologic infusionsdrug compoundingposition statementquinacrine

Online Treatment Reduces Chronic Knee Pain from Arthritis

Shereen Lehman  |  February 22, 2017

(Reuters Health)—A web-based program of exercise and coping skills training improves both function and pain in arthritic knees, a new study suggests. This kind of online therapy can greatly improve access to effective, nonsurgical and non-drug relief for people with osteoarthritis of the knee, researchers say. “Osteoarthritis is a leading cause of chronic knee pain…

Filed under:ConditionsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:Arthritisknee painonline therapyPainCOACHtelemedicine

Switch to Biosimilar Infliximab for IBD Slashes Drug Costs

Reuters Staff  |  February 17, 2017

NEW YORK—Inflammatory bowel disease (IBD) patients can be safely switched from originator infliximab to biosimilar infliximab using a managed-switching program, U.K. research shows. “Thus far, there does not appear to be any significant difference between the two infliximab products in terms of drug persistence, side effects, adverse reactions, disease activity, or blood tests, but ongoing…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsCT-P13drug costsIBDinfliximab

Quality Update Reporting Changes under MACRA

Mary Beth Nierengarten  |  February 16, 2017

With the termination of the Sustainable Growth Rate formula through the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), clinicians who participate in Medicare Part B will now be reimbursed through a new payment model called the Quality Payment Program (QPP). How It Works The QPP rewards the delivery of high-quality patient care via…

Filed under:Practice SupportProfessional Topics Tagged with:Advanced Alternative Payment MethodMedicare Access and CHIP Reauthorization Act of 2015 (MACRA)Medicare Part BMIPSQuality Payment Program (QPP)Quality Update Reportingsustainable growth rate formula

ACR Urges CMMI to Test Transparently: Coalition offers principles to guide CMS’s care innovation efforts

Susan Bernstein  |  February 16, 2017

The Center for Medicare and Medicaid Innovation (CMMI), which develops concepts for healthcare payment and service delivery, must be transparent and engaged with all stakeholders as it tests new models, according to a coalition of 30 associations. On Feb. 10, the Healthcare Leaders for Accountable Innovation in Medicare Coalition, which includes the ACR, released six…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Center for Medicare and Medicaid Innovation (CMMI)CMMIguideline principlesHealthcare Leaders for Accountable Innovation in Medicare CoalitionMACRAMedicare Access and CHIP Reauthorization Act of 2015Quality Payment Program

Anti-Interleukin-6 Therapy for Erdheim-Chester Disease Warrants Study

Stefanie D. Wade, MD, Michael A. Seidman, MD, Edward C. Jones, MD, Arnold Radu, MD, Ryan Paterson, MD, Vikram Deshpande, MD, John H. Stone, MD, & Mollie N. Carruthers, MD  |  February 16, 2017

Erdheim-Chester disease (ECD) is a rare, non-Langerhan’s cell histiocytosis characterized by tissue infiltration of CD68-positive and CD1a-negative foamy histiocytes.1 ECD was discovered as a lipid granulomatosis in 1930 by Jakob Erdheim and his pupil, William Chester, and approximately 500 cases have been described to date.1 ECD has a heterogeneous course and prognosis ranging from an…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:anti-interleukincase reportClinicalDiagnosisDiseaseErdheim-ChesterinflammatoryinterferonPathogenesistherapyTreatment

Rheumatology Research Abstracts Highlight Treatment for Hand OA, Risk of Depression in Lupus and More

Mary Beth Nierengarten  |  February 15, 2017

WASHINGTON, D.C.—What do treating hand osteoarthritis (OA) in the primary care setting, high financial strain and risk of depression in patients with lupus, prolonged sitting and cardiovascular disease, and sex-specific treatment after total hip arthroplasty have in common? They were all topics presented during a session titled ARHP I: Exemplary Abstracts at the 2016 ACR/ARHP…

Filed under:ConditionsInsuranceMeeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)cardiovascularDepressionhandhealthcare costinsuranceLupusOAOsteoarthritispatient careResearchrheumatologistrheumatologyriskSLESystemic lupus erythematosustotal hip arthroplasty

Multispecialty Team Approach Key to Diagnosing, Treating Neutrophilic Dermatosis

Thomas R. Collins  |  February 15, 2017

WASHINGTON, D.C.—Often, no clear explanation exists in neutrophilic dermatosis cases that links a patient’s skin disorder with an internal condition, expert Joseph Jorizzo, MD, professor, founder and former chair of the Dermatology Department at Wake Forest University in Winston-Salem, N.C., and professor of clinical dermatology at Wevascularill Cornell Medical College in New York, told attendees…

Filed under:ConditionsMeeting Reports Tagged with:2016 ACR/ARHP Annual MeetingArthritisBehçet’s diseaseboweldermatosisDiagnosisneutrophilic vascular reactionsreactive diseaserheumatologistrheumatologySweet's syndromeTreatment

  • « Previous Page
  • 1
  • …
  • 69
  • 70
  • 71
  • 72
  • 73
  • …
  • 125
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences